Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 177.

https://doi.org/10.1182/blood-2019-124050

Published: 2019

Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3916.

https://doi.org/10.1182/blood-2019-124034

Published: 2019

Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Blood (2019) 134 (Supplement_1): 2924.

https://doi.org/10.1182/blood-2019-128761

Published: 2019

Journal Articles

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, MD, Min Ji Jeon, Eun Sang Yu, MD, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD PhD, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park

Blood (2019) 134 (Supplement_1): 2227.

https://doi.org/10.1182/blood-2019-125269

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Chang Ki Min, MD PhD, Kihyun Kim, MD PhD, Seok Jin Kim, MD PhD, Dok Hyun Yoon, Sung-Soo Park, Seunghoon Han, MD PhD

Blood (2019) 134 (Supplement_1): 1847.

https://doi.org/10.1182/blood-2019-127643

Published: 2019

Journal Articles

A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy

Blood (2018) 132 (Supplement 1): 446.

https://doi.org/10.1182/blood-2018-99-112805

Published: 2018

Journal Articles

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Jorge E. Cortes, MD, Cristina Papayannidis, Catriona Jamieson, MD PhD, Gary J. Schiller, MD, Anna Candoni, MD, Brian Leber, MD, Claudia D. Baldus, MD, José A. Pérez-Simón, MD PhD, Weidong Wendy Ma, Corrado Gallo Stampino, Ashleigh O'Connell, Mirjana Zeremski, MD, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2018-99-110934

Published: 2018

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Blood (2018) 132 (Supplement 1): 1306.

https://doi.org/10.1182/blood-2018-99-112478

Published: 2018

Journal Articles

Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?

Osman Ilhan, MD, Guldane Cengiz Seval, Zubeyde Nur Ozkurt, Ali Ugur Ural, MD, Meltem Ayli, Omur Gokmen Sevindik, MD, Sinem Civriz Bozdag, MD, Meltem Kurt Yuksel, MD, Zafer Gulbas, MD, Muhit Özcan

Blood (2018) 132 (Supplement 1): 5729.

https://doi.org/10.1182/blood-2018-99-112339

Published: 2018

Journal Articles

Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review

Faiza Jamil, MD, Madeeha Shafqat, Ali Younas Khan, MD, Seren Durer, MD, Ceren Durer, MD, Zunairah Shah, MBBS, Anum Qureshi, Muhammad Abu Zar, MD, Ahmad Kamal, MD, Malik Qistas Ahmad, MD MBBS, Chaudhry Saad Sohail, MD, Insija Ilyas Selene, MBBS, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2018-99-109986

Published: 2018

Journal Articles

Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis (BKV-HC) Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Graham Tooker, Ashraf Z. Badros, MD, Jennifer Nishioka, PharmD, David Riedel, MD

Blood (2018) 132 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2018-99-110887

Published: 2018

Journal Articles

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Sara Bringhen, MD, Peter M. Voorhees, MD, Torben Plesner, MD, Claudia Paba-Prada, MD, Ulf-Henrik Mellqvist, MD, Jeffrey A Zonder, MD, Brandi Reeves, MD, Antonio Palumbo, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Eva Nordstrom, MSc, MBA, Hanan Zubair, MSc, Jakob Lindberg, MD PhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3150.

https://doi.org/10.1182/blood.V130.Suppl_1.3150.3150

Published: 2017

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2869.

https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869

Published: 2017

Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Torben Plesner, MD, Hendrik-Tobias Arkenau, Francesca Marianatal Gay, Monique C Minnema, Mario Boccadoro, Philippe Moreau, MDPhD, James D Cavenagh, Aurore Perrot, MD, Jacob Laubach, MD, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan Schecter, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 1828.

https://doi.org/10.1182/blood.V130.Suppl_1.1828.1828

Published: 2017

Journal Articles

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Blood (2017) 130 (Supplement 1): 1620.

https://doi.org/10.1182/blood.V130.Suppl_1.1620.1620

Published: 2017

Journal Articles

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Stephen Couban, MDBSc, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, MD PhD, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Ian Templeton, Francesco Passamonti

Blood (2017) 130 (Supplement 1): 4179.

https://doi.org/10.1182/blood.V130.Suppl_1.4179.4179

Published: 2017

NARROW

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?

Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review

Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis (BKV-HC) Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only